相关实验视频

Updated: Aug 12, 2026

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Published on: May 28, 2014

2,4-丁丁醇增强了西斯普拉丁和埃托胺在前列腺癌细胞系上的细胞毒性活性

Grzegorz Adamczuk¹, Ewelina Humeniuk¹, Kamila Adamczuk²

¹Independent Medical Biology Unit, Medical University, Lublin, Poland.

Annals of agricultural and environmental medicine : AAEM

|March 29, 2024

概括

2,4-丁丁醇 (2,4-DNP) 在LNCaP前列腺癌细胞中增强了化疗的细胞毒性作用. 这表明2,4-DNP可能通过破坏癌细胞能量代谢来帮助克服耐药性.

科学领域:

在瘤学瘤学.
癌症新陈代谢癌症新陈代谢
化学疗法耐药性抗化学疗法耐药性

背景情况:

药物耐药性限制了传统化疗在晚期癌症中的有效性.
向癌细胞能量代谢,特别是氧化酸化,是克服耐药性的潜在策略.
2,4-丁烯醇 (2,4-DNP) 是一种已知解氧化酸化的化合物,它改变了细胞能量生产.

研究的目的:

为了研究2,4-DNP对前列腺癌细胞对西斯丁和埃托波西德的敏感化潜力.
评估2,4-DNP是否可以增强这些化疗剂的作用.

主要方法:

在三个前列腺癌细胞系上进行了实验:LNCaP,PC-3和DU-145.
使用MTT试验评估了细胞活力.
分析了细胞循环,细胞亡,氧化应激 (CellRox染色) 和基因表达 (抗氧化防御,细胞循环抑制,药物耐药性载体,DNA修复).

主要成果:

2,4-DNP显著增强了西斯普拉丁和埃托的细胞毒性作用,仅在LNCaP细胞中.
LNCaP细胞表现出氧化代谢表型,使其与PC-3和DU-145细胞有所区别.

结论:

2,4-DNP在LNCaP细胞中的增强化疗效可能来自破坏的氧化还原平衡.
缺陷的DNA修复能力和前列腺癌细胞的氧化代谢表型有助于这种增强的效果.
2,4-DNP作为一种辅助疗法,有望在特定的前列腺癌亚型中克服抗化学性.

关键词:

西斯普拉丁 (cisplatin) 是一种制剂.这里是etoposide的位置.前列腺癌是前列腺癌.离合器的离合器

更多相关视频

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Author Spotlight: Combining Proximity Ligand Assay with Gamma-H2AX Staining to Characterize Protein Interactions in DNA Damage Response

Author Spotlight: Combining Proximity Ligand Assay with Gamma-H2AX Staining to Characterize Protein Interactions in DNA Damage Response

Published on: August 2, 2024

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...